`
`
`
` RESEARCH
`
`
`
`
` APPLICATION NUMBER:
`
`
`212477Orig1s000
`
`
` OFFICER/EMPLOYEE LIST
`
`
`
`
`
`
`
`
`
`MEMORANDUM
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`PUBLIC HEALTH SERVICE
`FOOD AND DRUG ADMINISTRATION
`CENTER FOR DRUG EVALUATION AND RESEARCH
`
`DATE:
`
`August 26, 2019
`
`TO:
`
`Administrative file for NDA 212477
`
`FROM:
`
`Philip Villasurda, PharmD, Regulatory Health Project Manager
`Division of Antiviral Products, Office of Antimicrobial Products
`
`SUBJECT: Officer/Employee List for NDA 212477
`
`APPLICATION/DRUG:
`
`NDA 212477, HARVONIĀ®, ledipasvir/sofosbuvir, oral pellets
`
`The following officers or employees of FDA participated in the decision to approve this
`application and consented to be identified on this list:
`
`Bimkrant, Debra B
`Chikhale, Elsbeth G
`Choi, Su-Young
`Davis, Nathan
`Dorantes, Angelica
`El-Kamary, Samer
`Englund, Erika
`Ghantous, Hanan
`Griffiths, LaShawn
`Harris, Sarah
`Hassan, Hazem
`Johnson, Anitra
`Kolejian, Sevan
`Lewis, David B
`Li, Ruojing
`Li, Zheng
`Lunn, George
`Min, Stacey
`Mishra, Lalji
`Murray, Jeffrey S
`O'Rear, Julian
`Ou, Mei
`Soldatova, Lyudmila
`Strayhorn,Suz~e
`
`Reference ID: 4489034
`
`
`
`Struble, Kimberly
`Swank, Kimberley
`Walker, Morgan
`Wilson, Valerie
`
`Reference ID: 4489034
`
`